Abstracts

729 – High Prevalence of Baseline NRTI Resistance in PWH Switched From Second-Line PI/r to B/F/TAF

Background Patients on PI/r-based regimens in resource-limited settings have high rates of NRTI resistance, but testing is rarely available.  Methods In this open-label prospective trial conducted at GHESKIO in Haiti, virologically suppressed adults on second-line PI/r-based ART were randomized to continue current regimen vs. switch to B/F/TAF. The primary endpoint was the proportion with HIV-1…

725 – Effect of SNG001, Inhaled IFN-β1a, on SARS-CoV-2 Diversity and Evolution

Background Interferon resistance has been implicated in SARS-CoV-2 escape from innate immune responses, but interferon’s specific impact on viral evolution is unknown. SNG001 is an inhaled interferon-β1a treatment for COVID-19 which was evaluated in the ACTIV-2/A5401 randomized placebo-controlled trial. Although SNG001 did not accelerate viral decay, there was a trend towards fewer hospitalizations in the…

746 – HIV Drug Resistance Among Individuals on Dolutegravir With Low-Level Viremia in Malawi

Background The clinical consequences of a low-level viremia (LLV) result (HIV-1 RNA 50-999 copies/mL) after a high viral load (VL) result (≥1,000 copies/mL) and intensive adherence counseling (IAC) are uncertain. The probability of future virological failure may be determined by the presence of drug resistance mutations (DRMs), but WHO does not recommend HIV drug resistance…

737 – Virologic Success on InSTI-Based ART Despite Archived InSTI DRMs

Background The relevance of drug resistance mutation (DRM) detection in HIV-1 proviral sequencing for the prediction of virological success on antiretroviral therapy (ART) remains unclear. In this retrospective study, we examined archived INSTI DRMs in people with HIV (PWH) virologically suppressed on INSTI-based regimens. Methods PWH with at least one HIV-1 integrase proviral sequencing were…

735 – HIV-1 Resistance Analysis of Treatment-Naive People With HIV and HBV Receiving B/F/TAF or DTG+F/TDF

Background In the ALLIANCE study (GS-US-380-4458; NCT03547908), bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was noninferior to dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) at achieving HIV-1 RNA suppression at Week (W) 48 in treatment-naïve adults with HIV-1/hepatitis B virus (HBV) coinfection, with high rates of suppression maintained through End of Study (EoS). We present HIV-1 resistance analyses through EoS for the B/F/TAF…

764 – Switching to DTG/3TC vs BIC/FTC/TAF and Steatotic Liver Disease: A Substudy of PASODOBLE Trial

Background Steatotic liver disease (SLD) is a common condition in PLWH, linked to overweight and associated metabolic disorders. Both INSTIs and TAF have been associated with weight gain in clinical trials and real-life studies. Likewise, TAF has also been associated with SLD. Controversial results have been reported regarding INSTIs and SLD. In virologically suppressed PLWH,…

723 – The Barrier to Escape From Broadly Neutralizing Antibodies Varies Between Different HIV-1 Isolates

Background Broadly neutralizing antibodies (bNAbs) against HIV-1 have re-invigorated research into antibody therapies and vaccination strategies for prevention, treatment, and cure of HIV-1 because of their unique ability to neutralize diverse HIV-1 strains. While many HIV-1 isolates are initially susceptible to bNAbs, their ability to acquire resistance is unknown. Understanding the evolutionary barriers to bNAb…

733 – Molecular Epidemiology of HIV-1 Transmitted Drug Resistance Among Subtypes Circulating in Italy

Background The aim of this study was to characterize subtypes circulation and transmitted drug resistance (TDR) in Italy by next-generation sequencing (NGS). Methods Routine plasma HIV-1 RNA NGS genotyping data were collected from newly diagnosed individuals over 2021-2024. TDR for PI, NRTI, NNRTI and INI, and genotypic susceptibility were evaluated through HIVdb (ver.9.6) with NGS…

741 – Impact of Resistance to Antiretroviral Therapy Among Veterans With Human Immunodeficiency Virus

Background Despite significant progress made in antiretroviral (ARV) therapy for human immunodeficiency virus-1 (HIV-1) treatment, one of the major challenges facing the efficacy of ARV is drug resistance. The objective of this study was to evaluate clinical outcomes associated with resistance to ARV among people with HIV (PWH).  Methods This national retrospective cohort study was…